Key result
Emerging strategies like radiation and gene therapy aim to prevent and treat coronary restenosis.
Why the study?
Restenosis after percutaneous coronary intervention remains a significant clinical problem despite advances such as intracoronary stents, necessitating evaluation of emerging prevention and treatment strategies.
This review summarizes the evolution of strategies to prevent and treat coronary restenosis, highlighting the shift from systemic pharmacologic agents to localized mechanical, radiation-based, and biological therapies.
Answers are grounded in this paper and cite their sources.
Restenosis limits PCI durability; leaves open effective prevention strategies for practice and targeted trials.
Percutaneous coronary intervention has become an increasingly attractive alternative to medical therapy and surgical revascularization for the treatment of coronary artery disease. Over 1.5 million interventional procedures are performed annually worldwide, with the rate of procedures performed continuing to rise dramatically. Restenosis following percutaneous coronary intervention occurs at rates of 20% to 40% and has remained the Achilles heel of the procedure. Numerous early attempts at the prevention of restenosis with oral pharmacologic agents, such as antithrombotic therapies, lipid lowering agents, vasodilators, and growth factor inhibitors, failed to show benefit in clinical trials. The introduction of intracoronary stents resulted in a 30% reduction in restenosis rates by abolishing the early vessel recoil following angioplasty. However, as more complex lesions underwent percutaneous coronary intervention with stenting, rates of “in-stent” restenosis remained high (20% to 30%). With technologic advances and greater understanding of vascular pathobiology, novel therapeutic strategies, such as local delivery of ionizing radiation, immunosuppressive agents, and gene therapy, have been deployed to prevent coronary restenosis. In addition, a number of mechanical and radiation-based strategies have been used to treat those patients who develop restenosis. This review considers these emerging strategies for the prevention and treatment of restenosis.
No takes yet. Share an insight, caveat, or question.
Dee et al. (2003) conducted a review in Coronary Restenosis. Emerging strategies for restenosis was evaluated. Emerging strategies such as ionizing radiation, immunosuppressive agents, and gene therapy are being deployed to prevent and treat coronary restenosis, which occurs at rates of 20% to 40%.
Synapse has enriched 10 related papers. Consider them for comparative context: